Europe Bipolar Disorder Market

Europe Bipolar Disorder Market Size (2023 to 2028)

The size of the Bipolar Disorder Market was valued at around USD 0.80 billion in 2023. This value is estimated to grow at a CAGR of 2.12% to reach USD 0.88 billion by 2028.

Growing incidence of bipolar disorders, unmet medical needs, strong pipeline drugs organized by pharmaceutical industries an unhealthy lifestyle of people is majorly increasing the growth of the market in the European region. An estimated 46 million people are diagnosing bipolar disorders globally, in which 52% of males and 48% are female. Technological advancements, a growing number of initiatives taken by the European governments to create awareness among people, and rising government support through funds and investments are positive signals co-operating to develop further. For instance, the introduction of the bipolar disorder phenomena database, sponsored by the National Institute of Mental Health (NIMH), provides full research information regarding the disorder's visible signs and complaints.

Insufficient amenities for bipolar disorder diagnosis, incapable equipment resulting in bipolar disorder, stringent government rules on misrecognition of the disorder, and inadequate equipment resulting in bipolar disorder being written as other personality disorder or depression. Rising adverse side-effects post to the usage of drugs during the treatment of disease, restraining the market growth in the region.

This research report on the European Bipolar Disorder Market has been segmented and sub-segmented into the following categories:

• By Type: Bipolar I Disorder, Bipolar II Disorder, and Cyclothymic Disorder
• By Mechanism of Action: Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Benzodiazepines, Serotonin-norepinephrine Reuptake Inhibitors, Beta-Blockers, Selective Serotonin Reuptake Inhibitors, and Others
• By Drug Class: Antianxiety Drugs, Mood Stabilizers, Antidepressant Drugs, Antipsychotic Drugs, and Anticonvulsants
• By Country: United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, and Rest of EU

Regional Analysis:

Europe is next to North America to govern the global bipolar disorder market. It is predicted to hike at a prominent growth rate during the forecast period due to technological advancements, growing awareness associated with bipolar disorder, and healthcare infrastructure advancements. 

Germany and the UK are expected to have notable growth from 2023 to 2028 due to the Y-O-Y increase in bipolar disorders. Technological advancements that have been used in developing genetic research on bipolar disorder and further augmenting the market Growing awareness related to bipolar disorders, a growing number of mergers and acquisitions among drug-producing companies fuel the market region. France, Italy, and Spain hold a significant share in the bipolar disorder market in Europe. 

The increasing awareness about bipolar disorder and the region's developed healthcare infrastructure is expected to be the significant driver of market growth.

Lead players in the market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Otsuka Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc